PMS2 mutations project: biospecimens procurement for characterization from high-risk population of canadian inuit
Ended Awarded Last action
- Contract number
- 75N91022F00022
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $266,647
Award facts
- Contract value 100% obligated
- $266,647.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$145,939 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Original award | $412,586 |
About this award
This is a federal contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract, valued at $266,647.00, is for the procurement of biospecimens from a high-risk population of Canadian Inuit to characterize genetic mutations related to the PMS2 gene as part of the PMS2 Mutations Project. The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type and has an ultimate completion date of August 31, 2025. This contract does not have a set-aside designation. Leidos Biomedical Research Inc. is an established Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing a wide range of biomedical research and facilities support services to federal agencies, with a focus on programs at the National Institutes of Health (NIH).
Quick answers
Who was awarded contract 75N91022F00022?
75N91022F00022 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2022.
How much is contract 75N91022F00022 worth?
The government has obligated $266,647 on 75N91022F00022.
Is contract 75N91022F00022 an order under another contract?
Yes. 75N91022F00022 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00022 competed?
The extent of competition for 75N91022F00022 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award